Literature DB >> 29736890

A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

S Y A Cheung1, J Parkinson2, U Wählby-Hamrén2, C D Dota2, Å M Kragh2, L Bergenholm3, T Vik4, T Collins5, C Arfvidsson6, C E Pollard5, H K Tomkinson7, B Hamrén2.   

Abstract

Drugs can affect the cardiovascular (CV) system either as an intended treatment or as an unwanted side effect. In both cases, drug-induced cardiotoxicities such as arrhythmia and unfavourable hemodynamic effects can occur, and be described using mathematical models; such a model informed approach can provide valuable information during drug development and can aid decision-making. However, in order to develop informative models, it is vital to understand CV physiology. The aims of this tutorial are to present (1) key background biological and medical aspects of the CV system, (2) CV electrophysiology, (3) CV safety concepts, (4) practical aspects of development of CV models and (5) regulatory expectations with a focus on using model informed and quantitative approaches to support nonclinical and clinical drug development. In addition, we share several case studies to provide practical information on project strategy (planning, key questions, assumptions setting, and experimental design) and mathematical models development that support decision-making during drug discovery and development.

Entities:  

Keywords:  Cardiovascular safety; Drug development; Drug discovery; Model Informed Drug Discovery and Development; QT; Regulatory; Translation

Mesh:

Substances:

Year:  2018        PMID: 29736890     DOI: 10.1007/s10928-018-9589-6

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  57 in total

1.  Systems pharmacology of arrhythmias.

Authors:  Seth I Berger; Avi Ma'ayan; Ravi Iyengar
Journal:  Sci Signal       Date:  2010-04-20       Impact factor: 8.192

2.  Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks.

Authors:  A R Harmer; N Abi-Gerges; A Easter; A Woods; C L Lawrence; B G Small; J-P Valentin; C E Pollard
Journal:  J Pharmacol Toxicol Methods       Date:  2007-09-26       Impact factor: 1.950

3.  Concepts and challenges in quantitative pharmacology and model-based drug development.

Authors:  Liping Zhang; Marc Pfister; Bernd Meibohm
Journal:  AAPS J       Date:  2008-11-12       Impact factor: 4.009

4.  Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop.

Authors:  Klaus Romero; Vikram Sinha; Sandra Allerheiligen; Meindert Danhof; Jose Pinheiro; Naomi Kruhlak; Yaning Wang; Sue-Jane Wang; John-Michael Sauer; J F Marier; Brian Corrigan; James Rogers; H J Lambers Heerspink; Tawanda Gumbo; Peter Vis; Paul Watkins; Tina Morrison; William Gillespie; Mark Forrest Gordon; Diane Stephenson; Debra Hanna; Marc Pfister; Richard Lalonde; Thomas Colatsky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-07       Impact factor: 2.745

Review 5.  An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk.

Authors:  Chris E Pollard; N Abi Gerges; M H Bridgland-Taylor; A Easter; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

Review 6.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Authors:  W S Redfern; L Carlsson; A S Davis; W G Lynch; I MacKenzie; S Palethorpe; P K S Siegl; I Strang; A T Sullivan; R Wallis; A J Camm; T G Hammond
Journal:  Cardiovasc Res       Date:  2003-04-01       Impact factor: 10.787

Review 7.  Assessing predictors of drug-induced torsade de pointes.

Authors:  Luiz Belardinelli; Charles Antzelevitch; Marc A Vos
Journal:  Trends Pharmacol Sci       Date:  2003-12       Impact factor: 14.819

8.  Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs.

Authors:  Helen Prior; Nick McMahon; Jason Schofield; Jean-Pierre Valentin
Journal:  J Pharmacol Toxicol Methods       Date:  2009-06-16       Impact factor: 1.950

9.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

Review 10.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

View more
  3 in total

1.  On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships.

Authors:  Christopher W McAleer; Amy Pointon; Christopher J Long; Rocky L Brighton; Benjamin D Wilkin; L Richard Bridges; Narasimham Narasimhan Sriram; Kristin Fabre; Robin McDougall; Victorine P Muse; Jerome T Mettetal; Abhishek Srivastava; Dominic Williams; Mark T Schnepper; Jeff L Roles; Michael L Shuler; James J Hickman; Lorna Ewart
Journal:  Sci Rep       Date:  2019-07-03       Impact factor: 4.379

2.  Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.

Authors:  Veronika Voronova; Marie Cullberg; Philip Delff; Joanna Parkinson; Corina Dota; Gaia Schiavon; Brijesh Maroj; Dinko Rekić; S Y Amy Cheung
Journal:  Br J Clin Pharmacol       Date:  2021-09-28       Impact factor: 3.716

Review 3.  KV11.1, NaV1.5, and CaV1.2 Transporter Proteins as Antitarget for Drug Cardiotoxicity.

Authors:  Magdalena Kowalska; Jacek Nowaczyk; Alicja Nowaczyk
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.